Sort by: after hours % change | delayed % change | gain open | gain high | gain close | publishing date
tags : Study symbols : Nvsef save search
Novartis investigational iptacopan Phase III study demonstrates clinically meaningful and statistically significant proteinuria reduction in patients with C3 glomerulopathy (C3G)
Published: 2023-12-11 (Crawled : 07:00) - globenewswire.com
NVS | News | $98.35 1.1% 0.0% 2.2M
|
Health Technology
|
| O: 0.75%
H: 0.55%
C: 0.27%
novartis study
Anti-inflammatory Therapeutics Market Size to Hit US$ 149.5 billion by 2031 | Exclusive Study by Transparency Market Research
Published: 2023-10-30 (Crawled : 09:00) - prnewswire.com
GLAXF | News | $19.54 -14.18% 2.6K
|
Health Technology
|
| O: -4.67%
H: 4.9%
C: 4.9%
SNYNF | News | $94.25 -2.18% 480
|
Health Technology
|
| O: 2.76%
H: 0.0%
C: 0.0%
PFE | News 4 | $26.27 -0.19% -0.15% 23M
|
Health Technology
|
| O: 0.43%
H: 1.46%
C: 1.03%
NVS | News | $98.35 1.1% 0.0% 2.2M
|
Health Technology
|
| O: 1.69%
H: 0.25%
C: -0.07%
JNJ | News | $148.53 -0.69% -0.14% 9.6M
|
Health Technology
|
| O: -1.39%
H: 0.79%
C: 0.64%
GSK | News | $40.86 -0.92% -0.15% 1.7M
|
Health Technology
|
| O: 2.29%
H: 0.44%
C: -0.23%
ABBV | News | $167.8 -1.03% -0.06% 4.1M
|
Health Technology
|
| O: 2.87%
H: 0.0%
C: 0.0%
SNY | News | $46.66 -2.16% -2.21% 1.7M
|
Health Technology
|
| O: -0.85%
H: 0.0%
C: 0.0%
research therapeutics study market
Novartis investigational atrasentan Phase III study demonstrates clinically meaningful and highly statistically significant proteinuria reduction in patients with IgA nephropathy (IgAN)
Published: 2023-10-30 (Crawled : 07:00) - globenewswire.com
NVS | News | $98.35 1.1% 0.0% 2.2M
|
Health Technology
|
| O: 1.69%
H: 0.25%
C: -0.07%
nephropathy novartis study
Kashiv BioSciences Enrolls First Patient in Phase III Clinical Study for ADL018, A Biosimilar Candidate to XOLAIR® (omalizumab)
Published: 2023-10-02 (Crawled : 17:00) - biospace.com/
NVS | News | $98.35 1.1% 0.0% 2.2M
|
Health Technology
|
| O: 0.19%
H: 0.03%
C: -0.5%
adl018 xolair candidate biosimilar study
Novartis investigational iptacopan Phase III study demonstrates clinically meaningful and highly statistically significant proteinuria reduction in patients with IgA nephropathy (IgAN)
Published: 2023-10-02 (Crawled : 06:00) - globenewswire.com
NVS | News | $98.35 1.1% 0.0% 2.2M
|
Health Technology
|
| O: 0.19%
H: 0.03%
C: -0.5%
nephropathy novartis study
Sandoz announces positive results from Mylight Phase lll study for biosimilar aflibercept
Published: 2023-08-15 (Crawled : 06:00) - globenewswire.com
NVS | News | $98.35 1.1% 0.0% 2.2M
|
Health Technology
|
| O: -0.32%
H: 0.18%
C: -0.44%
biosimilar positive results study
Cell Therapy Market Value to Reach US$ 54.6 Bn by 2032, States TMR Study
Published: 2022-12-19 (Crawled : 13:00) - prnewswire.com
NVS | News | $98.35 1.1% 0.0% 2.2M
|
Health Technology
|
| O: 0.0%
H: 0.09%
C: -0.32%
VCEL | $46.09 -0.71% -0.72% 200K
|
Health Technology
|
| O: -0.49%
H: 0.02%
C: -6.55%
therapy study market
Novartis investigational oral monotherapy iptacopan demonstrates clinically meaningful superiority over anti-C5 treatment in Phase III APPLY-PNH study
Published: 2022-10-24 (Crawled : 06:00) - globenewswire.com
NVS | News | $98.35 1.1% 0.0% 2.2M
|
Health Technology
|
| O: 0.6%
H: 0.84%
C: 0.19%
treatment novartis study
Bio-Thera Solutions Announces First Patient Dosed in Phase 1 Study for BAT2606, a Proposed Biosimilar of Nucala® (mepolizumab) Bio-Thera Solutions, Ltd. announced that dosing has begun in a Phase I cli...
Published: 2022-10-14 (Crawled : 13:00) - biospace.com/
NVS | News | $98.35 1.1% 0.0% 2.2M
|
Health Technology
|
| O: 0.17%
H: 0.8%
C: -0.75%
MS | News 0 d | $93.85 0.1% 0.0% 4.8M
|
Finance
|
| O: -2.63%
H: 2.37%
C: -2.5%
JNJ | News | $148.53 -0.69% -0.14% 9.6M
|
Health Technology
|
| O: 1.93%
H: 0.0%
C: 0.0%
DVA | News | $132.74 -0.87% 0.0% 470K
|
Health Services
|
| O: 0.65%
H: 1.88%
C: -0.77%
VRNA | $15.21 -2.44% -2.5% 320K
|
Health Technology
|
| O: 0.4%
H: 1.39%
C: -0.3%
UTHR | $237.06 1.11% 1.09% 610K
|
Health Technology
|
| O: 0.24%
H: 1.71%
C: 1.01%
NNVC | $1.15 0.88% 0.0% 14K
|
Health Technology
|
| O: 2.34%
H: 0.0%
C: 0.0%
bat2606 nucala solutions biosimilar study
Bio-Thera Solutions Announces First Patient Dosed in Phase 1 Study for BAT2606, a Proposed Biosimilar of Nucala® (mepolizumab)
Published: 2022-10-14 (Crawled : 11:00) - biospace.com/
NVS | News | $98.35 1.1% 0.0% 2.2M
|
Health Technology
|
| O: 0.17%
H: 0.8%
C: -0.75%
JNJ | News | $148.53 -0.69% -0.14% 9.6M
|
Health Technology
|
| O: 1.93%
H: 0.0%
C: 0.0%
bat2606 nucala solutions biosimilar study phase 1
Neuropathic Pain Therapeutics Market to Reach US$ 10.2 Bn by the end of 2030: TMR Study
Published: 2022-10-12 (Crawled : 18:00) - prnewswire.com
TEVA | $13.01 -0.68% 7.5M
|
Health Technology
|
| O: 0.12%
H: 0.56%
C: -0.12%
NVS | News | $98.35 1.1% 0.0% 2.2M
|
Health Technology
|
| O: -0.07%
H: 0.48%
C: -0.66%
JNJ | News | $148.53 -0.69% -0.14% 9.6M
|
Health Technology
|
| O: 1.29%
H: 0.0%
C: 0.0%
LLY | News | $732.2 -1.81% 0.18% 2.1M
|
Health Technology
|
| O: -0.07%
H: 1.92%
C: -0.86%
therapeutics study market
Macular Degeneration Treatment Market to Surpass US$ 21.1 Bn by 2031: TMR Study
Published: 2022-09-21 (Crawled : 02:00) - prnewswire.com
NVSEF | News | $96.0 6.88% 52K
|
Health Technology
|
| O: 0.98%
H: 0.0%
C: -1.99%
PFE | News 4 | $26.27 -0.19% -0.15% 23M
|
Health Technology
|
| O: 0.09%
H: 0.38%
C: -1.99%
NVS | News | $98.35 1.1% 0.0% 2.2M
|
Health Technology
|
| O: -0.73%
H: 0.04%
C: -1.85%
REGN | News | $906.55 -0.09% -0.08% 370K
|
Health Technology
|
| O: -0.47%
H: 1.24%
C: -2.32%
treatment macular study market
Value of Gout Therapeutics Market Estimated at US$ 4.9 Bn by 2031, TMR Study
Published: 2022-09-07 (Crawled : 12:00) - prnewswire.com
NVSEF | News | $96.0 6.88% 52K
|
Health Technology
|
| O: 4.71%
H: 0.0%
C: 0.0%
TAK | News | $13.23 -1.12% 0.0% 920K
|
Health Technology
|
| O: -1.5%
H: 1.21%
C: 1.06%
NVS | News | $98.35 1.1% 0.0% 2.2M
|
Health Technology
|
| O: 0.66%
H: 0.88%
C: 0.8%
therapeutics study market
Menopausal Hot Flashes Treatment Market Estimated to Rise at CAGR of 6% from 2019 to 2027, TMR Study
Published: 2022-08-25 (Crawled : 14:00) - prnewswire.com
GLAXF | News | $19.54 -14.18% 2.6K
|
Health Technology
|
| O: 0.03%
H: 0.0%
C: -1.29%
PFE | News 4 | $26.27 -0.19% -0.15% 23M
|
Health Technology
|
| O: 0.19%
H: 0.9%
C: 0.8%
NVO | News | $126.16 -1.93% -0.23% 3.1M
|
Health Technology
|
| O: -0.18%
H: 1.45%
C: 1.44%
NVS | News | $98.35 1.1% 0.0% 2.2M
|
Health Technology
|
| O: -0.28%
H: 0.13%
C: 0.04%
GSK | News | $40.86 -0.92% -0.15% 1.7M
|
Health Technology
|
| O: 0.0%
H: 0.63%
C: 0.6%
treatment study market
Novartis provides update on Phase III CANOPY-A study evaluating canakinumab as adjuvant treatment in non-small cell lung cancer
Published: 2022-08-15 (Crawled : 06:00) - globenewswire.com
NVS | News | $98.35 1.1% 0.0% 2.2M
|
Health Technology
|
| O: -0.49%
H: 0.44%
C: 0.14%
treatment lung novartis update cancer study
Gainers vs Losers
| 62% | 38% |
Top 10 Gainers
CSSE 4 | $0.4323 183.85% 64.77% 220M
|
Consumer Services
BOF | $1.99 70.09% 41.21% 110M
|
ILAG | $0.51 6.03% 40.62% 1.7M
|
LICN | $0.941 68.04% 40.49% 15M
|
AMST | $3.31 65.5% 39.58% 70M
|
Technology Services
MTC | $3.615 61.38% 38.04% 9.3M
|
Technology Services
WIMI | $1.15 58.53% 36.92% 19M
|
Technology Services
AIH | $0.45 12.5% 30.92% 320K
|
Health Services
MULN | News | $3.78 38.46% 27.78% 13M
|
Information
RILY | $29.86 37.48% 27.26% 12M
|
Finance
Your saved searches
Save your searches and get alerts when important news are released.